Literature DB >> 19516115

Retinal angiomatous proliferation: natural history and progression of visual loss.

Francesco Viola1, Amedeo Massacesi, Nicola Orzalesi, Roberto Ratiglia, Giovanni Staurenghi.   

Abstract

PURPOSE: To investigate the natural history and visual outcome in eyes with untreated retinal angiomatous proliferation, a neovascular form of age-related macular degeneration.
METHODS: Fourteen consecutive white patients (11 women, 78%; mean age, 74 years) with 16 eyes affected by retinal angiomatous proliferation were prospectively followed-up without treatment by means of complete ophthalmologic examinations at regular intervals, including best-corrected visual acuity and dynamic fluorescein and indocyanine green angiography using a scanning laser ophthalmoscope.
RESULTS: The patients were observed for a mean of 20 months (range, 6-44 months). Mean visual acuity in the eyes with retinal angiomatous proliferation was 0.48 at the initial examination, decreased to 0.23 after 6 months, and was 0.19 at the final examination, with a mean decrease of 6 lines from baseline. In 13 eyes (81%), visual acuity deteriorated by 2 Early Treatment Diabetic Retinopathy Study lines or worse by the time of the 6-month examination, and 31% of the patients had experienced severe loss of vision; the remaining 3 eyes (19%) showed a relatively stable clinical course and visual acuity. By the time of the final examination, visual acuity had decreased to 0.1 or worse in 11 eyes (69%), and 5 of the 14 patients (36%) were legally blind. At the final examination, 10 eyes (62%) showed a subretinal fibrosis and 9 (56%) showed a retinal choroidal anastomosis.
CONCLUSION: Retinal angiomatous proliferation is a distinct form of neovascular age-related macular degeneration with high vasogenic potential, having its own clinical course and visual prognosis. The poor visual outcome is because of the exudative nature of the retinal angiomatous proliferation, and progression to poor vision is common and rapid (within 3 months in faster cases, and within 1 year in slower cases). The treatment options for this type of neovascular lesion should be planned bearing in mind its unfavorable natural history.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19516115     DOI: 10.1097/IAE.0b013e3181a395cb

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  25 in total

Review 1.  [Pigment epithelial detachment in exudative macular degeneration: clinical characteristics and therapeutic options].

Authors:  A Lommatzsch
Journal:  Ophthalmologe       Date:  2010-12       Impact factor: 1.059

2.  Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Authors:  Ebenezer Daniel; James Shaffer; Gui-shuang Ying; Juan E Grunwald; Daniel F Martin; Glenn J Jaffe; Maureen G Maguire
Journal:  Ophthalmology       Date:  2015-12-08       Impact factor: 12.079

3.  Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.

Authors:  Han Joo Cho; Tae Gon Lee; Sang Youn Han; Hyoung Seok Kim; Jae Hui Kim; Jung Il Han; Young Ju Lew; Jong Woo Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-01       Impact factor: 3.117

4.  Retinal and choroidal vascular changes in coronary heart disease: an optical coherence tomography angiography study.

Authors:  J Wang; J Jiang; Y Zhang; Y W Qian; J F Zhang; Z L Wang
Journal:  Biomed Opt Express       Date:  2019-03-04       Impact factor: 3.732

5.  [Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections].

Authors:  M Maier; C Perz; J Bockmaier; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

Review 6.  Association of ARMS2/LOC387715 A69S, CFH Y402H, and CFH I62V polymorphisms with retinal angiomatous proliferation compared with typical age-related macular degeneration: a meta-analysis.

Authors:  Mohammad Hossein Jabbarpoor Bonyadi; Mehdi Yaseri; Mortaza Bonyadi; Masoud Soheilian
Journal:  Int Ophthalmol       Date:  2016-12-22       Impact factor: 2.031

7.  [Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].

Authors:  A Lommatzsch; B Heimes; M Gutfleisch; G Spital; M Dietzel; D Pauleikhoff
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

8.  Risk of scar in the comparison of age-related macular degeneration treatments trials.

Authors:  Ebenezer Daniel; Cynthia A Toth; Juan E Grunwald; Glenn J Jaffe; Daniel F Martin; Stuart L Fine; Jiayan Huang; Gui-shuang Ying; Stephanie A Hagstrom; Katrina Winter; Maureen G Maguire
Journal:  Ophthalmology       Date:  2013-12-04       Impact factor: 12.079

9.  Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano
Journal:  Jpn J Ophthalmol       Date:  2012-12-04       Impact factor: 2.447

10.  Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation.

Authors:  Tarek S Hemeida; Pearse A Keane; Laurie Dustin; Srinivas R Sadda; Amani A Fawzi
Journal:  Br J Ophthalmol       Date:  2009-10-23       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.